P4‐209: A Public Resource of Baseline Data From the Api Autosomal Dominant Alzheimer's Disease Colombia Trial

Reiman, Eric M.; Sink, Kaycee M.; Hu, Nan; Guthrie, Heather; Smith, Janice; Cho, William; Knoll, Katie L.; Langbaum, Jessica B.; Thomas, Ronald G.; Toga, Arthur W.; Chen, Kewei; Boker, Connie A.; Álvarez, Sergio; Quiroz, Yakeel T.; Romenets, Silvia Ríos; Lopera, Francisco; Tariot, Pierre N.

doi:10.1016/j.jalz.2018.07.030

Alzheimer's & Dementia

2018

DOI: 10.1016/j.jalz.2018.07.030

|View full text |Cite

P4‐209: A Public Resource of Baseline Data From the Api Autosomal Dominant Alzheimer's Disease Colombia Trial

Eric M. Reiman¹,

Kaycee M. Sink²,

Nan Hu³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

Ríos‐Romenets

Lopera

Sink³

et al. 2020

Alzheimer's & Dementia

View full text Add to dashboard Cite

Introduction The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo‐controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60‐year‐old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non‐carriers who receive placebo. Methods Of the 252 enrolled, we present data on a total of 242 mutation carriers and non‐carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity. Results We summarize demographic, clinical, cognitive, and behavioral data from 167 mutation carriers and 75 non‐carriers, 30 to 53 years of age. Carriers were significantly younger than non‐carriers ((mean age ± SD) 37 ± 5 vs 42 ± 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 ± 1.4 vs 29.2 ± 1.0), and had consistently lower memory scores. Discussion Although PSEN1 E280A mutation carriers in the Trial are cognitively unimpaired, they have slightly lower MMSE and memory scores than non‐carriers. Their demographic characteristics are representative of the local population.

show abstract

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

Ríos‐Romenets

Lopera

Sink³

et al. 2020

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P4‐209: A Public Resource of Baseline Data From the Api Autosomal Dominant Alzheimer's Disease Colombia Trial

Cited by 1 publication

References 0 publications

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

Contact Info

Product

Resources

About